2022
TCT-58 FANTOM II Trial: Safety and Performance Study of the Fantom Sirolimus-Eluting Bioresorbable Coronary Scaffold—Final: 5-Year Clinical Outcomes
Lutz M, Abizaid A, Carrie D, Dudek D, Lansky A. TCT-58 FANTOM II Trial: Safety and Performance Study of the Fantom Sirolimus-Eluting Bioresorbable Coronary Scaffold—Final: 5-Year Clinical Outcomes. Journal Of The American College Of Cardiology 2022, 80: b23-b24. DOI: 10.1016/j.jacc.2022.08.070.Peer-Reviewed Original ResearchBioresorbable coronary scaffoldClinical outcomes
2020
Long‐term serial functional evaluation after implantation of the Fantom sirolimus‐eluting bioresorbable coronary scaffold
Saito Y, Cristea E, Bouras G, Abizaid A, Lutz M, Carrié D, Weber‐Albers J, Dudek D, Anderson J, Lansky A, Investigators T. Long‐term serial functional evaluation after implantation of the Fantom sirolimus‐eluting bioresorbable coronary scaffold. Catheterization And Cardiovascular Interventions 2020, 97: 431-436. PMID: 32077590, DOI: 10.1002/ccd.28804.Peer-Reviewed Original ResearchConceptsPost-percutaneous coronary interventionQuantitative flow ratioBioresorbable coronary scaffoldTarget vessel revascularizationVessel revascularizationFunctional ischemiaStable coronary artery diseaseTime of revascularizationCoronary artery diseaseFractional flow reserveQFR assessmentII trialAngiographic outcomesCoronary interventionUnstable anginaArtery diseaseQFR valueWire-based fractional flow reserveSignificant lesionsFlow reservePatientsTarget vesselRevascularizationQFR analysisFunctional evaluation
2019
TCT-177 Long-Term Serial Functional Evaluation After Implantation of the Fantom Sirolimus-Eluting Bioresorbable Coronary Scaffold: The FANTOM II study
Saito Y, Bouras G, Abizaid A, Lutz M, Carrié D, Weber-Albers J, Anderson J, Lansky A. TCT-177 Long-Term Serial Functional Evaluation After Implantation of the Fantom Sirolimus-Eluting Bioresorbable Coronary Scaffold: The FANTOM II study. Journal Of The American College Of Cardiology 2019, 74: b176. DOI: 10.1016/j.jacc.2019.08.234.Peer-Reviewed Original Research
2017
TCT-332 FANTOM II Trial: Safety & Performance Study of the Fantom Sirolimus-Eluting Bioresorbable Coronary Scaffold – First Report on Initial 24 Month Outcomes
Abizaid A, Didier C, Frey N, Lutz M, Weber-Albers J, Dudek D, Chevalier B, Lansky A, Anderson J. TCT-332 FANTOM II Trial: Safety & Performance Study of the Fantom Sirolimus-Eluting Bioresorbable Coronary Scaffold – First Report on Initial 24 Month Outcomes. Journal Of The American College Of Cardiology 2017, 70: b136. DOI: 10.1016/j.jacc.2017.09.420.Peer-Reviewed Original Research